The first patient has been treated in Repare Therapeutics' camonsertib monotherapy expansion in ATM-mutated non-small cell lung cancer. We are grateful to our patients, investigators, and team who share in our mission to bring therapies to patients in need. Learn more here: https://lnkd.in/eESd9yaN#precisiononcology#clinicaltrials#NSCLC
Amazing to see the gene (ATM) my grad work was focused on 20 years ago finally becoming a part of the treatment profile! This is very personally fulfilling to me. Glad to see this happening…let’s continue to shorten the cycles of basic research to therapy!
Join us tomorrow, Sunday, June 2, during the ASCO Annual Meeting for a groundbreaking poster presentation between 9:00 a.m. to 12:00 p.m. Our recent study utilizing the ConcertAI Oncology Dataset has revealed promising results for patients with metastatic castration-resistant prostate cancer. Through a collaboration with Merck and AstraZeneca our real-world analysis has demonstrated that early treatment with Olaparib monotherapy could potentially enhance the duration of therapy and overall survival rates for these patients. This study underscores the importance of leveraging data to make informed treatment decisions that can ultimately improve patient outcomes.
Read abstract: https://hubs.ly/Q02z9qws0#ASCO24#OncologyResearch#RealWorldData#OlaparibMonotherapy#PatientCare
Over the past weekend, Ripal Gandhi, M.D., FSVM, FSIR presented, “Advances in Pancreatic Cancer: Trans-arterial Therapy on the Horizon,” at the Symposium on Clinical Interventional Oncology (CIO). Dr. Gandhi highlighted RenovoRx's proprietary Trans-Arterial Micro-Perfusion (TAMP™) therapy platform designed to ensure precise delivery for targeted treatment of cancer, and its potential for increased safety, tolerance, and improved efficacy. View the presentation here: https://bit.ly/3LDnQz8#CIO2023#PancreaticCancer#LocallyAdvancedPancreaticCancer#LAPC
Over the past weekend, Ripal Gandhi, M.D., FSVM, FSIR presented, “Advances in Pancreatic Cancer: Trans-arterial Therapy on the Horizon,” at the Symposium on Clinical Interventional Oncology (CIO). Dr. Gandhi highlighted RenovoRx's proprietary Trans-Arterial Micro-Perfusion (TAMP™) therapy platform designed to ensure precise delivery for targeted treatment of cancer, and its potential for increased safety, tolerance, and improved efficacy. View the presentation here: https://bit.ly/3LDnQz8#CIO2023#PancreaticCancer#LocallyAdvancedPancreaticCancer#LAPC
📣 Exciting CUTANA CUT&Tag application!
Here, EpiCypher pAG-Tn5 and CUT&Tag protocol were used to study localization of cGAS in cancer cells, which helped uncover novel connections between SWI/SNF chromatin remodelers and mTORC2 signaling in chemoresistant colorectal cancer. These results provide promising new strategies for therapeutic development!
https://hubs.la/Q02KB1cn0
The Endocannabinoid System as a Pharmacological Target for
New Cancer Therapies.
Effects of MAGL and FAAH on tumour-immune interactions.
https://lnkd.in/gNei9eiU
Scientist at Medical University of Warsaw | Former Postdoctoral Research Fellow at Prof. MC Hung’s Lab | h-index 24 | NK cell research and cancer immunotherapy
Over the past weekend, Ripal Gandhi, M.D., FSVM, FSIR presented, “Advances in Pancreatic Cancer: Trans-arterial Therapy on the Horizon,” at the Symposium on Clinical Interventional Oncology (CIO). Dr. Gandhi highlighted RenovoRx's proprietary Trans-Arterial Micro-Perfusion (TAMP™) therapy platform designed to ensure precise delivery for targeted treatment of cancer, and its potential for increased safety, tolerance, and improved efficacy. View the presentation here: https://bit.ly/3LDnQz8#CIO2023#PancreaticCancer#LocallyAdvancedPancreaticCancer#LAPC
Tagrisso plus chemotherapy extended median progression-free survival by nearly 9 months in EGFR-mutated advanced lung cancer in FLAURA2 phase III trial - AstraZeneca https://lnkd.in/eMMuCeY2
This webinar will present topics on drug interactions with prostate cancer treatment, survivorship care pathways for men on ADT and an interesting case study on complications which can occur from prostate cancer treatments.
#ANZUNS#Bayer#ProstateCancer
Leading Digital Product Innovator | Revolutionizing Healthcare Technology
2moAmazing to see the gene (ATM) my grad work was focused on 20 years ago finally becoming a part of the treatment profile! This is very personally fulfilling to me. Glad to see this happening…let’s continue to shorten the cycles of basic research to therapy!